Jagadeesha's brain, the first juvenile Huntington's Disease donation in India, offers hope for vital neurodegenerative ...

Teva stock rocketed into a profit-taking zone Wednesday after the company put up a big sales beat for its drug Austedo, in ...

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaign TD is a chronic movement ...

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching 'The Other TD' campaignTD is a chronic movement disorder impacting one in four people who take certain pr ...

A peculiar and uncontrollable mass movement gripped the city of Strasbourg in the summer of 1518 when dozens of residents began dancing in the streets without any apparent reason or music. Historians ...

In Q3, $687 million of its Neurocrine’s income came from sales of Ingrezza, its treatment for the movement disorder tardive dyskinesia, as well as chorea associated with Huntington’s disease. Rounding ...

Addressing these gaps begins with recognizing SUD as a chronic condition that requires ongoing management within the scope of nursing facility services. Although not expected to deliver comprehensive ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2025.

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last year's ...